Objective
Drug treatment is often inefficient. Only 30–60% of patients respond properly to treatment with e.g. antidepressants, beta-blockers, statins and antipsychotics. Furthermore, adverse drug reactions (ADRs) frequently occur and cause about 7% of all hospital admissions, a frequency that is increased to 30% in elderly subjects above 70 years of age. This is due to a great extent to pharmacokinetics differences.
Epigenetic modifications have been demonstrated to potentially participate in the regulation of ~60 human ADME genes. A correlation between the gene’s epigenetic state and possible influence on drug therapy outcome has been experimentally established only in relation to a few ADME genes.
Several drugs with epigenetic actions are currently used or on clinical trials. The best examples are DNA Methyltransferases (DNMTs) and Histone Deacetylase (HDACs) inhibitors.
In this project, we propose to elucidate the substantial unexplained fraction of interindividual variability in drug response and metabolism using a 3D multi-cell in vitro model of human liver in comparison to transcriptome and phenotype data obtained from a bank of 130 human livers with the following AIMS:
AIM1: to unmask the epigenetically regulated ADME genes
AIM2: to evaluate the epigenetically regulated ADME genes as interindividual variability biomarkers
A list of epimarks of interindividual variation of drug ADME processes will be generated.
AIM3: to test the epigenetic influence of candidate drugs. Our objective is to identify the specific ADME genes epigenetically altered by each drug treatment and elucidate the possibilities of interindividual variation in the ADME processes for each of the tested drugs.
This approach is extensively multidisciplinary and multisectorial. The experimental design includes tissue bioengineering techniques to develop liver organotypic cultures, drug metabolism functional profiling, and molecular biology approaches, from the perspective of cutting-edge technology.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- natural sciences biological sciences genetics DNA
- medical and health sciences basic medicine pharmacology and pharmacy pharmacokinetics
- medical and health sciences basic medicine pharmacology and pharmacy adverse drug reactions
- natural sciences biological sciences molecular biology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2012-CIG
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MC-CIG - Support for training and career development of researcher (CIG)
Coordinator
171 77 STOCKHOLM
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.